Article Text

Download PDFPDF

Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
  1. Rui V Duarte1,2,
  2. Jon H Raphael1,2,
  3. Jane L Southall2,
  4. Mourad H Labib3,
  5. Andrew J Whallett4,
  6. Robert L Ashford1
  1. 1Faculty of Health, Birmingham City University, Birmingham, UK
  2. 2Department of Pain Management, Russells Hall Hospital, Dudley, UK
  3. 3Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK
  4. 4Department of Rheumatology, Russells Hall Hospital, Dudley, UK
  1. Correspondence to Dr Rui V Duarte; ruivduarte{at}gmail.com

Abstract

Objectives This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopaenia and/or osteoporosis in those diagnosed with hypogonadism.

Design Observational study using health data routinely collected for non-research purposes.

Setting Department of Pain Management, Russells Hall Hospital, Dudley, UK.

Patients Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculating the free testosterone level. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results Based on the calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T score ≤−2.5 SD) was detected in three patients (21.4%) and osteopaenia (defined as a T score between −1.0 and −2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusions This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and the bone mineral density levels followed by appropriate treatment may be of paramount importance to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

  • chronic pain
  • hypogonadism
  • drug delivery systems, implantable
  • bone density

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.